Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
Alexander R. Lyon(Royal Brompton Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Daniel J. Lenihan(Saint Francis Medical Center), Frank Ruschitzka(Kantonsspital St. Gallen), Zaza Iakobishvili(Ben-Gurion University of the Negev), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Johann Bauersachs(Medizinische Hochschule Hannover), Javid J. Moslehi(Cardiovascular Institute of the South), Thomas Thum(Medizinische Hochschule Hannover), John D. Groarke(Edinburgh Cancer Research), Christine Brezden‐Masley(Mount Sinai Hospital), Daniela Cardinale(European Institute of Oncology), Ana Barac(Inova Fairfax Hospital), Rudolf A. de Boer(Erasmus MC), Stephan von Haehling(German Centre for Cardiovascular Research), Ariane Vieira Scarlatelli Macedo(Santa Casa Hospital), Susan Dent(Government of the United States of America), María Sol Andrés(Royal Brompton Hospital), Charlotte Manisty(National Institutes of Health), Christoph Maack(Universitätsklinikum Würzburg), Robert F. Cornell(Dana-Farber Cancer Institute), Andrew J.S. Coats(The Heart Research Institute), Aaron L. Sverdlov(Hunter New England Local Health District), David J. Wright(University of Liverpool), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Michael G. Fradley(University of South Florida), Carlo G. Tocchetti(Federico II University Hospital), Dimitrios Farmakis(National and Kapodistrian University of Athens), Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Stuart D. Rosen(Royal Brompton & Harefield NHS Foundation Trust), Radek Pudil(Charles University), Ludhmila Abrahão Hajjar(Universidade de São Paulo), Hugues de Lavallade(King's College Hospital), Paaladinesh Thavendiranathan(University of Toronto), Jutta Bergler‐Klein, Petar Seferović, Alain Cohen‐Solal(Inserm), Susannah Stanway(Royal Marsden NHS Foundation Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Ashutosh Wechelaker(Amyloidosis Foundation), Helena Earl(University of Cambridge), Bonnie Ky(Virginia Commonwealth University), Hadi Skouri(University of Balamand), Dragana Milojković(Imperial College Healthcare NHS Trust), Tomas G. Neilan(Albert Einstein College of Medicine), Li Ling Tan(Chengdu University of Traditional Chinese Medicine), Joerg Herrmann(Mayo Clinic), Markus S. Anker(Humboldt-Universität zu Berlin), Thomas Suter(University of Bern), Yu. N. Belenkov(Sechenov University), Ronald Witteles(Alnylam Pharmaceuticals (United States))
Cited by 767
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k